Clinical Trial Update: Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing aliskiren plus valsartan with ramipril plus telmisartan in hypertensive patients to assess effects on the RAAS; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Altace (ramipril) (ramipril)
• Diovan (valsartan) (valsartan)
• Micardis (telmisartan) (telmisartan)
• Tekturna (aliskiren) (aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 2 | Status: COMPLETED